BTAI Key Statistics, Chart & Performance
The current stock price of BTAI is 1.84 USD. In the past month the price increased by 2.22%. In the past year, price decreased by -66.57%.
BTAI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BTAI. When comparing the yearly performance of all stocks, BTAI is a bad performer in the overall market: 93.48% of all stocks are doing better.
BTAI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BTAI. BTAI has a bad profitability rating. Also its financial health evaluation is rather negative.
BTAI Financial Highlights
Over the last trailing twelve months BTAI reported a non-GAAP Earnings per Share(EPS) of -9.7. The EPS increased by 71.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.28% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BTAI Forecast & Estimates
11 analysts have analysed BTAI and the average price target is 16.12 USD. This implies a price increase of 775.87% is expected in the next year compared to the current price of 1.84.
For the next year, analysts expect an EPS growth of 74.67% and a revenue growth -79.33% for BTAI
BTAI Ownership
BTAI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About BTAI
Company Profile
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Company Info
BIOXCEL THERAPEUTICS INC
555 Long Wharf Dr
New Haven CONNECTICUT 06511 US
CEO: Vimal Mehta
Employees: 37
Phone: 12036438060
BIOXCEL THERAPEUTICS INC / BTAI FAQ
Can you describe the business of BIOXCEL THERAPEUTICS INC?
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Can you provide the latest stock price for BIOXCEL THERAPEUTICS INC?
The current stock price of BTAI is 1.84 USD. The price decreased by -3.66% in the last trading session.
Does BTAI stock pay dividends?
BTAI does not pay a dividend.
What is the ChartMill technical and fundamental rating of BTAI stock?
BTAI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is BIOXCEL THERAPEUTICS INC (BTAI) stock traded?
BTAI stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of BTAI stock?
BIOXCEL THERAPEUTICS INC (BTAI) operates in the Health Care sector and the Biotechnology industry.
Can you provide the short interest for BTAI stock?
The outstanding short interest for BIOXCEL THERAPEUTICS INC (BTAI) is 4.92% of its float.